Brief: Beyond Air Affiliate Beyond Cancer Doses Initial Patient In First-In-Human Phase 1 Study Of Ultra-High Concentration Nitric Oxide Therapy At Tel Aviv Sourasky Medical Center
23/08/2022 13:07
Aug 23 (Reuters) - Beyond Air Inc XAIR.O :
* BEYOND AIR® AFFILIATE BEYOND CANCER™ DOSES INITIAL PATIENT
IN
FIRST-IN-HUMAN PHASE 1 STUDY OF ULTRA-HIGH CONCENTRATION NITRIC
OXIDE THERAPY AT TEL AVIV SOURASKY MEDICAL CENTER (ICHILOV)
Source text for Eikon: ID:nGNX62yzhb
Further company coverage: XAIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyond Air
See all newsBrief: Beyond Air Enters Definitive Agreement To Sell Its NeuroNOS Stake To UNIVO Pharmaceutical Industries In Exchange For Equity And Milestone Payments
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook
Beyond Air Inc expected to post a loss of $10.80 a share - Earnings Preview
NASDAQ RESUMED AT 04:00 AM